珠海润都制药股份有限公司关于氢氯噻嗪获得 化学原料药上市申请批准通知书的公告

Group 1 - The company, Zhuhai Runduo Pharmaceutical Co., Ltd., has received the approval notice for the listing application of hydrochlorothiazide as a chemical raw material drug from the National Medical Products Administration [1][2] - The drug hydrochlorothiazide is indicated for conditions such as edema, hypertension, central or renal diabetes insipidus, and nephrolithiasis [3] - The approval of this drug enhances the company's product portfolio and strengthens its full industry chain layout, positively impacting future operational performance [3] Group 2 - The application for the drug was submitted in April 2024, with the approval process involving additional research and documentation submitted in 2025 [2] - The approval is based on compliance with the relevant requirements of the Drug Administration Law of the People's Republic of China [1]